Sort   by:  
 Page size 
MetabolomicsCell Membrane Remodeling Mediates Polymyxin B Resistance in Klebsiella pneumoniae: An Integrated Proteomics and Metabolomics Study
Polymyxin B (PB) is introduced into the clinic as the last-line therapy against carbapenem-resistant Klebsiella pneumoniae (CRKP). Unfortunately, increased resistance to PB in Klebsiella pneumoniae (K. pneumoniae) has threatened global health. Resistance of K. pneumoniae ...
2022-03-04 | MTBLS4132 | MetaboLights
ProteomicsThe proteome data of extracellular vesicles derived from human umbilical cord and bone marrow mesenchymal stem cells
The protein samples stored at -80 °C were thawed and treated with lysis buffer (8M urea, 1% protease inhibitor, 50mM NH4HCO3) for 5 minutes in room temperature. After ultrasonic cracking on ice and centrifugation at 14000g for 10 min at 20 °C, the amount of total protein of each MSC sample was detec...
ORGANISM(S): Homo Sapiens 
PXD042977 |
ProteomicsThe proteome data of human mesenchymal stem cell derived from healthy donors
The protein samples stored at -80 °C were thawed and treated with lysis buffer (8M urea, 1% protease inhibitor, 50mM NH4HCO3) for 5 minutes in room temperature. After ultrasonic cracking on ice and centrifugation at 14000g for 10 min at 20 °C, the amount of total protein of each MSC sample was detec...
ORGANISM(S): Homo Sapiens 
2023-06-12 | PXD033812 |
ProteomicsMolecular Glue Degraders of HuR to Treat BRAF-Mutant Colorectal Cancer
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
PXD077365 |
ProteomicsMolecular Glue Degraders of the RNA Binding Protein HuR to Treat BRAF-Mutant Colorectal Cancer
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2025-12-21 | PXD072281 |
Sort   by:  
 Page size